Web Analytics




Home Tags Posts tagged with "Zhang Nan"

Tag: Zhang Nan

Pharma IPO Income Indicators and Risks
Practitioners' perspectives

Income indicators and risks for pharma IPOs

By Zhang Nan, W&H Law Firm

How income indicators and sales expenses impact risks in pharmaceutical IPOs under regulatory scrutiny

0

LATEST ON LAW.ASIA

MOST READ ON LAW.ASIA

Jonathan Crompton Joins Broadfield

Broadfield appoints Asia disputes and investigations head

HKEX opens up

By Rodney Teoh, Allbright Law Offices

SEHK’s 24 July 2026 conclusions launch flexible Hong Kong listing reforms amid global IPO rivalry

Chapter 18A Listing Preparation

Proving core product eligibility for chapter 18A listing

Ankit Jain joins JSA

Ankit Jain to bolster JSA’s disputes practice

GSK's Chimagen Biosciences asset acquisition

GSK to acquire Chimagen asset in deal worth up to USD750m

Simpson-Thacher

Simpson Thacher advises on USD3.9bn JDP V fund

Correspondents

India Healthcare Investmentvideo

Healthcare investment in India: The PE playbook

By Ayush Jain, Bharucha & Partners
Philippine Citizenship By Marriage

Bride and prejudice: Gendered paths to Philippine citizenship

By Jewel M Culala, ACCRALAW
AI investments in Indiavideo

Rethinking due diligence for Indian AI deals

By Vandana Pai and Shreya Sreesankar, Bharucha & Partners
NCLAT shields enforcement actions

PMLA free pass dilutes insolvency moratorium

By Ambar Bhushan and Divyam Sharma, Bharucha & Partners
Follow Law.asia
Law firms Awards Events Legal jobs • Post a job
About us Archive Subscribe Contact us
Please send any press releases, deal announcements, details of new hires, newsletters and any other news items to: news@law.asia
© Copyright 2026 Law.asia Limited. All rights reserved.

Follow us on LinkedIn

Follow now